Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Efudex

Fluorouracil

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Efudex:

 BioPortfolio Logo
Oceanside Pharmaceuticals Announces Launch of Librax(R) AG 23rd November, 2009 Valeant Pharmaceuticals International
ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide
Valeant Pharmaceuticals Reports First Quarter Financial Results 5th May, 2009 Valeant Pharmaceuticals International
- Revenue up 17%, 36% at constant exchange rates - GAAP EPS $0.37, adjusted Cash EPS $0.46 - Cash Flow from operations $51 million - Increased guidance for 2009, Cash EPS to $1.70 - 1.90 ALISO

This page has been viewed 21 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Efudex across BioPortfolio, or for Efudex Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.